<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143843</url>
  </required_header>
  <id_info>
    <org_study_id>FSV5-003</org_study_id>
    <nct_id>NCT02143843</nct_id>
  </id_info>
  <brief_title>An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product</brief_title>
  <official_title>An Open-Label Extension (OLE) Study to Evaluate the Safety of the ForSight VISION5 Product in Subjects With Open-Angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-002</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ForSight Vision5, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ForSight Vision5, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and comfort of the ForSight VISION5 product
      when used for up to 13 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>13 months</time_frame>
    <description>Incidence and severity of ocular and non-ocular adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>13 months</time_frame>
    <description>Intraocular Pressure (IOP)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient-reported comfort assessment</measure>
    <time_frame>13 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maintenance of IOP-reduction</measure>
    <time_frame>13 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of rescue treatment</measure>
    <time_frame>13 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Retention duration of the ForSight VISION5 Product</measure>
    <time_frame>13 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Primary Open-Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the ForSight VISION5 Product in both eyes (OU).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost Ocular Ring</intervention_name>
    <description>Bimatoprost Ocular Ring used continuously for 7 months, then replaced with a new Bimatoprost Ocular Ring and used continuously for another 6 months.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>&quot;Lumigan&quot; is the branded name of bimatoprost in eye drop form</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completed FSV5-002 study.

          2. Written informed consent prior to any study procedure.

          3. Willingness to comply with the visit schedule.

        Exclusion Criteria:

          1. Participation in an investigational drug or device study other than FSV5-002 within
             the past 6 months or anticipated participation during the study period.

          2. Subjects who will require contact lens use during the study period.

          3. Any condition or situation (such as uncontrolled systemic disease) that, in the
             Investigator's opinion, might confound the results of the study, may put the subject
             at significant risk or might interfere with the subject's ability to participate in
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2014</study_first_submitted>
  <study_first_submitted_qc>May 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <disposition_first_submitted>February 14, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 14, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 15, 2017</disposition_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share IPD at this time. Product is investigational and not approved.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

